Bio Details

Richard Chin, M.D., has served on our board of directors since 2025. Since 2021, he has served as the managing director of Ascendant Venture LLC, a family office and venture studio that has incubated several life sciences companies; since 2026, he has also served as the Chief Executive Officer of EmberWorks, LLC, an off-grid telecommunications company. He has also served as the Chief Executive Officer and a board member of AdoraPet Biosciences, Inc., a biotechnology startup focused on pets, since 2022. From 2012 to 2021, he served as Chief Executive Officer and a board member of Kindred Biosciences, Inc., a public biotechnology company focused on companion animals that was acquired by Elanco in 2021. From 2008 to 2011, Dr. Chin served as Chief Executive Officer of Institute for OneWorld Health, a nonprofit biotechnology company developing drugs for neglected diseases. In addition, from 2006 to 2008, he served as Chief Executive Officer of OXiGENE, Inc., a public biotechnology company developing vascular targeting drugs for oncology and ophthalmology. Prior to that, Dr. Chin served in various leadership roles in clinical development and medical affairs. He currently serves on the board of directors of several private biosciences companies, including Bio Usawa Inc., VETmAb Biosciences, Inc. and Lifeguard Biosciences, Inc., as well as two nonprofit organizations, the Center for Asian American Media and the Sand Mandala Foundation. 

Dr. Chin holds a B.A. in biology from Harvard College, an M.A. and B.A. in law from Oxford University, and a medical degree from Harvard Medical School.